Molecular Partners AG (MOLN) AI Stock Analysis

Molecular Partners AG is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic proteins. At the forefront of its pipeline is Abicipar, a DARPin candidate in Phase III clinical trials for neovascular wet age-related macular degeneration and diabetic macular edema. The company is also advancing MP0420 and MP0423 for COVID-19, MP0310 and MP0317 for immuno-oncology, MP0274 for HER2-positive cancers, MP0533 for acute myeloid leukemia, and MP0250. Headquartered in Schlieren, Switzerland, Molecular Partners maintains strategic collaborations with industry partners including Novartis AG, Amgen SA, Allergan, Inc., and AbbVie Inc.

Molecular Partners generated $0 in revenue over the trailing twelve months ended June 30, 2026, with quarterly revenue growth falling 100.0% year-over-year. The company's five-year revenue compound annual growth rate from FY2019 to FY2024 was -24.6%. Annual revenue peaked in FY2022 at $189.6M with net income of $117.9M and an operating margin of 61.5%. However, revenue dropped 96.3% to $7.0M in FY2023 and fell 29.4% to $5.0M in FY2024. For FY2024, the operating margin was -1231.7% and net income was -$54.0M, or -$1.85 per share. Research and development expenses totaled $48.6M in FY2024.

As of June 30, 2026, Molecular Partners held $67.7M in cash and short-term investments against $3.0M in total debt, leaving net cash of $64.7M. Total assets stood at $75.4M and shareholders' equity was $58.3M, supported by a current ratio of 7.27 and a debt-to-equity ratio of 0.05. In FY2024, operating cash flow was -$59.2M and free cash flow was -$60.0M. Capital expenditures in FY2025 were $714,000, while the company's share count expanded 64.3% over five years.

Molecular Partners carries a market capitalization of $136.4M and an enterprise value of $77.7M. The stock trades at a forward price-to-earnings ratio of 1.7x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 156.6x compared to the peer median of 4.1x, while its enterprise value-to-EBITDA ratio is 1.2x versus the peer median of 12.0x. Over the past year, the stock returned -7.5%, lagging the 16.8% return for the S&P 500 benchmark. Over five years, the shares fell 82.0%, trailing the S&P 500 return of 83.0%.

Wall Street coverage consists of 4 Strong Buy ratings and 1 Hold rating, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $10.49, implying upside of 194.7% from the last close of $3.56. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $5.6M and an EPS of -$1.11. For the next fiscal year, 3 analysts estimate revenue of $30.7M and an EPS of -$0.14. Molecular Partners beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Molecular Partners AG (MOLN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MOLN income statement, MOLN balance sheet, MOLN key metrics, MOLN analyst forecast, MOLN chart. See the MOLN stock overview for the latest quote and news.